OncoMatch/Clinical Trials/NCT05147467
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Is NCT05147467 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies APG2575 for chronic lymphocytic leukemia.
Treatment: APG2575 — The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: BTK inhibitor — refractory, recurrent, or intolerant
Refractory, recurrent, or intolerant to BTK inhibitors
Must have received: immunochemotherapy — refractory, recurrent, or intolerant
Refractory, recurrent, or intolerant to...immunochemotherapy
Cannot have received: BCL2 inhibitor
Received Bcl-2 inhibitor treatment
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: if within 24 months
Prior history of allogeneic hematopoietic stem cell transplantation...within 24 months
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: if within 24 months
Prior history of...autologous hematopoietic stem cell transplantation within 24 months
Cannot have received: adoptive cell immunotherapy
Exception: if within 24 months
Prior history of...adoptive cell immunotherapy...within 24 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05147467 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCL2 inhibitor, allogeneic hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages